These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 32029398)

  • 1. Impact of Body Mass Index on the Incidence of Bortezomib-induced Peripheral Neuropathy in Patients With Newly Diagnosed Multiple Myeloma.
    Moore DC; Ringley JT; Nix D; Muslimani A
    Clin Lymphoma Myeloma Leuk; 2020 Mar; 20(3):168-173. PubMed ID: 32029398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Black Race on Peripheral Neuropathy in Patients With Newly Diagnosed Multiple Myeloma Receiving Bortezomib Induction.
    Sun LF; Maples KT; Hall KH; Liu Y; Cao Y; Joseph NS; Hofmeister CC; Kaufman JL; Dhodapkar M; Nooka AK; Lonial S; Harvey RD
    JCO Oncol Pract; 2023 Sep; 19(9):793-798. PubMed ID: 37418682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of concomitant dexamethasone dosing schedule on bortezomib-induced peripheral neuropathy in multiple myeloma.
    Kumar SK; Laubach JP; Giove TJ; Quick M; Neuwirth R; Yung G; Rajkumar SV; Richardson PG
    Br J Haematol; 2017 Sep; 178(5):756-763. PubMed ID: 28591409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low serum vitamin D occurs commonly among multiple myeloma patients treated with bortezomib and/or thalidomide and is associated with severe neuropathy.
    Wang J; Udd KA; Vidisheva A; Swift RA; Spektor TM; Bravin E; Ibrahim E; Treisman J; Masri M; Berenson JR
    Support Care Cancer; 2016 Jul; 24(7):3105-10. PubMed ID: 26902977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics and risk factors of bortezomib induced peripheral neuropathy: A systematic review of phase III trials.
    Li T; Timmins HC; King T; Kiernan MC; Goldstein D; Park SB
    Hematol Oncol; 2020 Aug; 38(3):229-243. PubMed ID: 31873944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of the frequency of bortezomib neuropathy in patients with multiple myeloma diagnosis with normal and abnormal genetic characteristics.
    Kul AN; Ipek Y
    J Oncol Pharm Pract; 2023 Oct; 29(7):1652-1660. PubMed ID: 36237141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patients.
    Corso A; Mangiacavalli S; Varettoni M; Pascutto C; Zappasodi P; Lazzarino M
    Leuk Res; 2010 Apr; 34(4):471-4. PubMed ID: 19674790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Bortezomib-Induced Neuropathy Using Total Neuropathy Score (Reduced and Clinical Versions) and NCI CTCAE v4.0 in Newly Diagnosed Patients With Multiple Myeloma Receiving Bortezomib-Based Induction.
    Lakshman A; Modi M; Prakash G; Malhotra P; Khadwal A; Jain S; Kumari S; Varma N; Varma S
    Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):513-519.e1. PubMed ID: 28842138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcutaneous bortezomib in multiple myeloma patients induces similar therapeutic response rates as intravenous application but it does not reduce the incidence of peripheral neuropathy.
    Minarik J; Pavlicek P; Pour L; Pika T; Maisnar V; Spicka I; Jarkovsky J; Krejci M; Bacovsky J; Radocha J; Straub J; Kessler P; Wrobel M; Walterova L; Sykora M; Obernauerova J; Brozova L; Gregora E; Adamova D; Gumulec J; Adam Z; Scudla V; Hajek R;
    PLoS One; 2015; 10(4):e0123866. PubMed ID: 25875484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meta-analysis of incidence and risk of peripheral neuropathy associated with intravenous bortezomib.
    Peng L; Ye X; Zhou Y; Zhang J; Zhao Q
    Support Care Cancer; 2015 Sep; 23(9):2813-24. PubMed ID: 25676487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial.
    Broyl A; Corthals SL; Jongen JL; van der Holt B; Kuiper R; de Knegt Y; van Duin M; el Jarari L; Bertsch U; Lokhorst HM; Durie BG; Goldschmidt H; Sonneveld P
    Lancet Oncol; 2010 Nov; 11(11):1057-65. PubMed ID: 20864405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Incidence and Risk of Peripheral Neuropathy Caused by Intravenous and Subcutaneous Injection of Bortezomib].
    Liu ZQ; Xia HL; Li CJ; Xia L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Oct; 27(5):1654-1663. PubMed ID: 31607328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial.
    Merz M; Salwender H; Haenel M; Mai EK; Bertsch U; Kunz C; Hielscher T; Blau IW; Scheid C; Hose D; Seckinger A; Jauch A; Hillengass J; Raab MS; Schurich B; Munder M; Brossart P; Gerecke C; Lindemann HW; Zeis M; Weisel K; Duerig J; Goldschmidt H
    Haematologica; 2016 Dec; 101(12):e485-e487. PubMed ID: 27540135
    [No Abstract]   [Full Text] [Related]  

  • 14. Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis.
    Sidana S; Narkhede M; Elson P; Hastings D; Faiman B; Valent J; Samaras C; Hamilton K; Liu HK; Smith MR; Reu FJ
    PLoS One; 2017; 12(3):e0172996. PubMed ID: 28278302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial.
    Merz M; Salwender H; Haenel M; Mai EK; Bertsch U; Kunz C; Hielscher T; Blau IW; Scheid C; Hose D; Seckinger A; Jauch A; Hillengass J; Raab MS; Schurich B; Munder M; Schmidt-Wolf IG; Gerecke C; Lindemann HW; Zeis M; Weisel K; Duerig J; Goldschmidt H
    Haematologica; 2015 Jul; 100(7):964-9. PubMed ID: 25840597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A genetic variant study of bortezomib-induced peripheral neuropathy in Chinese multiple myeloma patients.
    Zhang Y; Zhang H; Wang J; Wei X; Qu YI; Xu F; Zhang L
    Oncol Res; 2024; 32(5):955-963. PubMed ID: 38686049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
    Popat R; Brown SR; Flanagan L; Hall A; Gregory W; Kishore B; Streetly M; Oakervee H; Yong K; Cook G; Low E; Cavenagh J;
    Lancet Haematol; 2016 Dec; 3(12):e572-e580. PubMed ID: 27843120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
    Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
    Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacovigilance of patients with multiple myeloma being treated with bortezomib and/or thalidomide.
    Castro TB; Hallack Neto AE; Atalla A; Ribeiro LC
    Braz J Med Biol Res; 2016; 49(6):e5128. PubMed ID: 27254660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of subcutaneous versus intravenous bortezomib in multiple myeloma: a meta-analysis
.
    Hu B; Zhou Q; Wu T; Zhuang L; Yi L; Cao J; Yang X; Wang J
    Int J Clin Pharmacol Ther; 2017 Apr; 55(4):329-338. PubMed ID: 28079515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.